Mark P Ettinger
Overview
Explore the profile of Mark P Ettinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
White H, Petrie C, Landschulz W, MacLean D, Taylor A, Lyles K, et al.
J Clin Endocrinol Metab
. 2009 Jan;
94(4):1198-206.
PMID: 19174493
Context: GH secretion declines with age, possibly contributing to reduced muscle mass, strength, and function. GH secretagogues (GHS) may increase muscle mass and physical performance. Objectives/design: We conducted a randomized,...
2.
Greenspan S, Bone H, Ettinger M, Hanley D, Lindsay R, Zanchetta J, et al.
Ann Intern Med
. 2007 Mar;
146(5):326-39.
PMID: 17339618
Background: Recombinant human parathyroid hormone (1-84) (PTH) increases bone mass and strength and improves bone quality by stimulating new bone formation. Objective: To determine the safety of PTH and its...
3.
Ettinger M, Gallagher R, MacCosbe P
Endocr Pract
. 2006 Sep;
12(5):522-8.
PMID: 17002926
Objective: To compare medication persistence among patients receiving daily orally administered bisphosphonates with persistence among patients receiving weekly orally administered bisphosphonates to ascertain whether less frequent dosing is associated with...
4.
Gold D, Alexander I, Ettinger M
Ann Pharmacother
. 2006 Jun;
40(6):1143-50.
PMID: 16735667
Objective: To review the evidence on adherence with bisphosphonates and evolving dosing strategies for osteoporosis treatment. Data Sources: Articles were identified by searching MEDLINE (1975-December 2005) using the following terms:...
5.
Ettinger M, Felsenberg D, Harris S, Wasnich R, Skag A, Hiltbrunner V, et al.
J Rheumatol
. 2005 Oct;
32(10):1968-74.
PMID: 16206354
Objective: The risk of osteoporosis increases exponentially with age. Elderly patients, who are often frail, have declining functional status and take multiple medications, and require osteoporosis therapies that are not...
6.
Chesnut C, Ettinger M, Miller P, Baylink D, Emkey R, Harris S, et al.
Curr Med Res Opin
. 2005 Apr;
21(3):391-401.
PMID: 15811208
Objectives: BONE (oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe) determined whether less frequent dosing of ibandronate (dose-free interval > 2 months) provided similar antifracture efficacy to...
7.
Hodsman A, Hanley D, Ettinger M, Bolognese M, Fox J, Metcalfe A, et al.
J Clin Endocrinol Metab
. 2003 Nov;
88(11):5212-20.
PMID: 14602752
Daily sc injections of N-terminal analogs of PTH increase bone mass and decrease fractures in osteoporotic women. We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the...
8.
Ettinger M
Arch Intern Med
. 2003 Oct;
163(18):2237-46.
PMID: 14557222
As the older population increases, the incidence of osteoporotic fractures is expected to dramatically rise during the next few decades. Older patients are much more susceptible to fracture at any...
9.
Ettinger M, Littlejohn T, Schwartz S, Weiss S, McIlwain H, Heymsfield S, et al.
JAMA
. 2003 Apr;
289(14):1826-32.
PMID: 12684362
Context: Obese individuals tend to resist the weight-regulating effects of exogenously administered leptin. A genetically engineered recombinant human variant ciliary neurotrophic factor (rhvCNTF) that signals through leptinlike pathways in the...
10.
Dujovne C, Ettinger M, McNeer J, Lipka L, LeBeaut A, Suresh R, et al.
Am J Cardiol
. 2002 Nov;
90(10):1092-7.
PMID: 12423709
The efficacy and safety of ezetimibe, a new cholesterol absorption inhibitor, was evaluated in this randomized, double-blind, placebo-controlled trial of 892 patients with primary hypercholesterolemia. After > or =2 weeks...